이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

전립선암(PCa)으로 안드로겐 박탈 요법을 받는 남성을 위한 생활습관 중재

2026년 9월 29일 업데이트: Thomas Jefferson University

전립선암 치료를 위한 안드로겐 박탈 요법을 받는 남성을 위한 라이프스타일 중재

This small study tested a 3-month text-based health coaching program for men with prostate cancer on hormone therapy. The program was feasible and well accepted, with participants showing good engagement and some improvements in weight and quality of life. However, differences between groups were not statistically significant, so larger studies are needed to confirm the benefits.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

Background/Objectives: This study aimed to assess the feasibility and acceptability of a 3-month health coaching intervention to promote PNF and healthy diet for men on ADT for PCa.

Methods: The study was carried out via a two-armed randomized controlled trial including 40 patients with PCa at a medical center in Philadelphia. During the 3-month period, the intervention group (PNF+) received health coaching utilizing an interactive text message system, and the control group received healthy eating text messages for the same duration. The outcome variables were feasibility and acceptability.

연구 유형

중재적

등록 (실제)

40

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • Thomas Jefferson University Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:

    • Must be 18 years of age or older
    • Provide signed and dated informed consent form
    • Had a histological diagnosis of PCa (Stage IIA-IVB)
    • Are beginning or receiving ADT (including medical castration with LHRH-agonist-antagonist androgen receptor modulators) for PCa with an anticipated duration of ≥ 3 months. The ADT is defined as: (a) Gonadotropin Releasing Hormone (GNRH) agonist (including leuprolide [Lupron/Eligard], goserelin [Zoladex], triptorelin [Trelstar], histrelin [Vantas], and abiraterone [Zytiga]) alone; (b) GNRH agonist with oral androgen receptor blockade (including bicalutamide [Casodex], flutamide [Eulexin], and enzalutamide [Xtandi]), and (c) GNRH agonist, oral androgen receptor blockade, and 5-alpha reductase inhibitors. Patients on androgen receptor modulators and second-generation androgen receptor antagonists will qualify.
    • Intermittent ADT will be allowed as long as the overall duration is more than 3 months.
    • BMI ≥25 kg/m2
    • Radiation therapy will be allowed concurrently.
    • Willing and able to comply with the protocol for the duration of the study
    • Able to speak, read and write English
    • Has a mobile phone with TXT capability.

Exclusion Criteria:

  • An individual who meets any of the following criteria will be excluded from participation in this study:

    • Inability to tolerate a normal diet (may include an active malabsorption syndrome at time of consent (i.e. Crohn's disease, major bowel resection leading to permanent malabsorption)
    • Patients on concurrent chemotherapy will be excluded.
    • ECOG score > 2
    • Medications such as finasteride/dutasteride/saw palmetto are not allowed.
    • Insulin injection or glyburide medication

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Prolonged Nightly Fasting (PNF+)

Participants will be invited to participate in weekly calls with a trained health coach during the and will be encouraged to fast at least 12 hours nightly, gradually increasing to 16 hours. This will be complemented by an interactive TXT system. Participants will interact with the study platform, to report when they begin and end their overnight fasting as well as their sleeping behaviors. The platform will provide positive reinforcement messages when their fasting goal is successfully met as well as guidance and tips for fasting. The health eating attention control group: participants will

participants will be invited to participate in weekly counseling calls with a trained health coach and will be encouraged to fast at least 12 hours nightly, gradually increasing to 16 hours. This will be complemented by an interactive TXT system. Participants will interact with the study platform, to report when they begin and end their overnight fasting as well as their sleep pattern data. The platform will provide positive reinforcement messages when their fasting goal is successfully met as well as guidance and tips for fasting.

다른 이름들:
  • 상호작용적 TXT 통합 중재
  • 시간 제한적 섭식
  • PNF+
활성 비교기: Healthy Diet Group

The health eating attention control group: participants will receive text messages twice a day to focus on information and tips on general healthy eating, based on AICR evidence-based materials.

Healthy Diet Group will receive general messages about healthy diet derived from AICR.

다른 이름들:
  • 건강 식습관 주의 통제 집단

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Accrual Rate
기간: 12 months

Percentage of eligible participants who consent and enroll in the study.

12 months
Attrition Rate
기간: Approximately 3 months

Percentage of enrolled participants completing post-intervention follow-up.

Approximately 3 months
Time-Restricted Eating Compliance
기간: Approximately 3 months

Percentage of participants compliant with 70% of the intervention days (70% of 90 days = 63 days) with suggested TRE

Approximately 3 months
Number of Adverse Events
기간: Approximately 3 months

Number of Adverse Events

Approximately 3 months
Patient Satisfaction
기간: Approximately 3 months

Patient satisfaction, as measured from Client Satisfaction Quesionnaire-8 item version (CSQ-8), a validated measure that elicits the client's perspective on the value of serves received37. Qualitatively, a structured interview guide will be developed to assess the behavioral determinants (barriers and facilitators to adoption of the 16:8 TRE, including the usefulness and practicality of the PNF+ intervention and any specific feedback for improvement. Sample questions include: asking participants to: 1) identify the greatest benefit from PNF+ program; 2) indicate the greatest challenge from be compliant with the PNF+ program; 3) describe the way in which their neurological function or memory had changed (improved or worsened); and 4) indicate the driving force that bring them to participate in the PNF+ program.

Approximately 3 months

기타 결과 측정

결과 측정
측정값 설명
기간
Fatigue
기간: Baseline up to 3 months

Fatigue will be measured by the Functional Assessment of Chronic Illness Therapy-Fatigue short form. The FACIT-F includes 13 items, such as "I feel fatigued" and "I feel weak all over." Items are scored on a range from 0 to 52 with higher scores indicating better quality of life or less fatigue. This will be measured at baseline and all follow ups to inform future trials. The pre-post change scores will be calculated for each participant and standard deviations of the change scores. Intervention effects will be tested using Wilcoxon tests or Fisher's exact tests, as appropriate.

Baseline up to 3 months
Change in Weight
기간: Baseline up to 3 months

Weight: participants' weight will be collected from EMR and asked about self-reported weights during health coaching check in. The pre-post change scores will be calculated for each participant and standard deviations of the change scores. Intervention effects will be tested using Wilcoxon tests or Fisher's exact tests, as appropriate.

Baseline up to 3 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Kuang-Yi Wen, PhD, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 5월 2일

기본 완료 (실제)

2025년 5월 2일

연구 완료 (실제)

2025년 5월 2일

연구 등록 날짜

최초 제출

2026년 3월 4일

QC 기준을 충족하는 최초 제출

2026년 3월 4일

처음 게시됨 (실제)

2026년 3월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 29일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 19S.725
  • JT 42246 (기타 식별자: JeffTrial Number)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .